Seminoma

This phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This phase 3 trial compares two chemotherapy approaches for people with germ cell tumors that have returned or not responded to initial treatment. One group receives standard-dose chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP). The other receives high-dose chemothe…

This study tests whether a surgery called retroperitoneal lymph node dissection (RPLND) can be used as the first treatment for men with early-stage testicular seminoma that has spread to lymph nodes in the abdomen. The goal is to see if this surgery can control the cancer while c…

This phase 2 trial tests whether reducing the intensity of chemotherapy and radiation can safely treat stage IIA/B seminoma, a type of testicular cancer. About 135 patients will receive either carboplatin alone or a combination of cisplatin and etoposide, along with lower-dose ra…

This phase II trial is testing the drug cabozantinib in 50 patients with germ cell tumors that have not responded to standard chemotherapy. The goal is to see if the drug can stop or slow tumor growth. Patients take cabozantinib daily until the disease worsens or side effects bec…

This phase 3 trial tests whether one course of BEP chemotherapy works better than one course of carboplatin to prevent seminoma testicular cancer from coming back after surgery. It includes 348 men with stage I seminoma who have risk factors like a large tumor or rete testis inva…

This study is testing whether a blood marker called miRNA 371 can predict if germ cell tumors (a type of cancer) will return after treatment. Researchers will collect blood samples from 956 newly diagnosed patients and track who has a relapse. The goal is to see if this marker ca…